Role of biologics in intractable urticaria

Biologics: Targets and Therapy

Volumn 9, Issue , 2015, Pages 25-33

  Cooke, Andrew ^a   Bulkhi, Adeeb ^a,b   Casale, Thomas B ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Anakinra; Canakinumab; Hronic urticaria; Intravenous immunoglobulin; Omalizumab

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; BIOLOGICAL PRODUCT; CANAKINUMAB; ETANERCEPT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; OMALIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ABNORMAL BLOOD PRESSURE; ADD ON THERAPY; ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; ARM PAIN; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEST TIGHTNESS; CHILL; CHOLINERGIC URTICARIA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC URTICARIA; CINCA SYNDROME; CLINICAL TRIAL (TOPIC); COLD URTICARIA; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; DEMYELINATING DISEASE; DERMATITIS; DERMOGRAPHISM; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; FRACTURE; GUILLAIN BARRE SYNDROME; HEADACHE; HEART ARREST; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; JUVENILE RHEUMATOID ARTHRITIS; LEG PAIN; LEUKOPENIA; LIVER INJURY; LUNG TOXICITY; LUPUS VULGARIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; MYASTHENIA GRAVIS; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; OTALGIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCHNITZLER SYNDROME; SIDE EFFECT; SINUSITIS; SOLAR URTICARIA; SOLID TUMOR; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIAL VASCULITIS; VASCULITIS; VITILIGO; VOMITING; WEGENER GRANULOMATOSIS; WHEEZING;

EID: 84936859334     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S63839     Document Type: Article

References (68)

1. Zuberbier T, Aberer W, Asero R, et al; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887
2. O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2):197–201
3. Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc. 2008;29(5):439–446
4. Engin B, Uguz F, Yilmaz E, Ozdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2008;22(1):36–40
5. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4(6):326–331
6. Powell RJ, Du Toit GL, Siddique N, et al; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5): 631–650
7. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4): 664–672
8. Maurer M, Weller K, Bindslev-Jensen C, etal. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317–330
9. Bernstein JA, Lang DM, Khan DA, etal. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277
10. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998;138(4):635–638
11. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559
12. Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61(2):253–260; discussion 261
13. Kaplan AP. Therapy of chronic urticaria: a simple, modern approach. Ann Allergy Asthma Immunol. 2014;112(5):419–425
14. Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996;106(5):1001–1006
15. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005; 35(4):408–416
16. Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy. 2011;9(1):2
17. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015; 135(2):337–342. e2
18. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2(10):773–786
19. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117(6):1415–1418
20. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979–981
21. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99(2):190–193
22. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol. 2010;90(4):443–444
23. Romano C, Sellitto A, De Fanis U, etal. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104(1):95–97
24. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57–62
25. Altman MC, Naimi DR. Omalizumab for chronic urticaria. N Engl J Med. 2013;368(26):2528–2530
26. Brodska P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol. 2012;4(3):275–280
27. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75
28. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(2):247–249
29. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569–573
30. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209. e5
31. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–573. e1
32. Maurer M, Rosen K, Hsieh HJ, etal. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013; 368(10):924–935
33. Kaplan A, Ledford D, Ashby M, etal. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109
34. Bernstein JA, Saini SS, Maurer M, et al. Efficacy of omalizumab in patients with chronic idiopathic/spontaneous urticaria with different background therapy: post hoc analysis of ASTERIA I, ASTERIA II, and GLACIAL studies. J Allergy Clin Immunol. 2014;133(2 Suppl):AB117
35. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–290
36. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3): 176–189
37. Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol. 2014;14(6):509–515
38. Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–245
39. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–323; quiz 324–315
40. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207
41. O’Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138(1): 101–106
42. Watkins C, Peiris E, Saleh H, Krishnaswamy G. Intravenous immunoglobulin as a potential therapy for refractory urticaria – a review. Inflamm Allergy Drug Targets. 2012;11(5):375–381
43. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22): 1599–1604
44. Grattan CE, Francis DM, Slater NG, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339(8801):1078–1080
45. Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol. 2007;39(7):237–242
46. Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy. 2000;55(11):1099–1101
47. Correia I, Silva J, Filipe P, Gomes M. Solar urticaria treated successfully with intravenous high-dose immunoglobulin: a case report. Photodermatol Photoimmunol Photomed. 2008;24(6):330–331
48. Darras S, Segard M, Mortier L, Bonnevalle A, Thomas P. Urticaire solaire traitée par l’association immunoglobulines polyvalentes et PUVAthérapie. [Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy]. Ann Dermatol Venereol. 2004;131(1 Pt 1): 65–69. French
49. Aubin F, Porcher R, Jeanmougin M, et al; Société Française de Photodermatologie. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study. J Am Acad Dermatol. 2014;71(5):948–953. e1
50. Mallipeddi R, Grattan CE. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol. 2007; 32(3):333–334
51. Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol. 2009;123(2):510–511; author reply 511
52. Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol. 2011;128(6):1354–1355
53. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol. 2003;49(5 Suppl):S283–S285
54. Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol. 1999;103(2 Pt 1):307–314
55. Piconi S, Trabattoni D, Iemoli E, et al. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol. 2002;128(1): 59–66
56. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol. 2007;119(3):752–754
57. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol. 2011;64(6):1221–1222
58. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990; 343(6256):336–340
59. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67
60. Federici S, Sormani MP, Ozen S, et al; for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheumat Dis. Epub January 30, 2015
61. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–305
62. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34–42
63. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–2425
64. Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–568
65. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010; 5:38
66. Lachmann HJ, Hawkins PN. Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther. 2009;11(1):212
67. Neel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13(10):1035–1041
68. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;(1):CD005121.